CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vera Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vera Therapeutics Inc
8000 Marina Boulevard,, Suite 120
Phone: (650) 770-0077p:650 770-0077 BRISBANE, CA  94005  United States Ticker: VERAVERA

Business Summary
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Non-Executive Chairman of the Board Michael M.Morrissey 62 5/24/2022 5/24/2022
President, Chief Executive Officer, Founder, Director MarshallFordyce 49 5/1/2016 5/1/2016
Chief Financial Officer Sean P.Grant 38 7/1/2021 7/1/2021
7 additional Officers and Directors records available in full report.

Business Names
Business Name
VERA
VERA THERAPEUTICS, INC

General Information
Number of Employees: 51 (As of 12/31/2023)
Outstanding Shares: 54,452,029 (As of 3/20/2024)
Shareholders: 21
Stock Exchange: NASD
Federal Tax Id: 812744449
Fax Number: (302) 655-5049
Email Address: info@veratx.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024